Cyclerion Therapeutics Operating Expenses Growth & History (CYCN)
Cyclerion Therapeutics's operating expenses was $7.0M for fiscal 2025.
View full Cyclerion Therapeutics company overviewCyclerion Therapeutics annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.0M | $1.4M | +25.21% |
| 2024 | 2024-12-31 | $5.6M | −$7.3M | −56.54% |
| 2023 | 2023-12-31 | $13.0M | −$5.9M | −31.25% |
| 2022 | 2022-12-31 | $18.8M | −$40.3M | −68.15% |
| 2021 | 2021-12-31 | $59.1M | −$24.4M | −29.23% |
| 2020 | 2020-12-31 | $83.6M | −$46.0M | −35.50% |
| 2019 | 2019-12-31 | $129.5M | $14.3M | +12.40% |
| 2018 | 2018-12-31 | $115.3M | — | — |
Cyclerion Therapeutics quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.8M | $6,000 | +0.34% |
| Q1 2026 | 2026-03-31 | $3.2M | $1.7M | +108.65% |
| Q4 2025 | 2025-12-31 | $1.9M | $559,000 | +42.87% |
| Q3 2025 | 2025-09-30 | $1.9M | $559,000 | +42.28% |
| Q2 2025 | 2025-06-30 | $1.8M | $381,000 | +27.53% |
| Q1 2025 | 2025-03-31 | $1.5M | −$80,000 | −4.94% |
| Q4 2024 | 2024-12-31 | $1.3M | −$492,000 | −27.39% |
| Q3 2024 | 2024-09-30 | $1.3M | −$4.7M | −78.02% |
| Q2 2024 | 2024-06-30 | $1.4M | −$481,000 | −25.79% |
| Q1 2024 | 2024-03-31 | $1.6M | −$1.7M | −50.60% |
| Q4 2023 | 2023-12-31 | $1.8M | — | — |
| Q3 2023 | 2023-09-30 | $6.0M | $1.5M | +33.13% |
| Q2 2023 | 2023-06-30 | $1.9M | −$11.9M | −86.43% |
| Q1 2023 | 2023-03-31 | $3.3M | −$10.4M | −76.09% |
| Q3 2022 | 2022-09-30 | $4.5M | −$7.1M | −61.16% |
| Q2 2022 | 2022-06-30 | $13.7M | −$5.4M | −28.35% |
| Q1 2022 | 2022-03-31 | $13.7M | $238,000 | +1.77% |
| Q4 2021 | 2021-12-31 | $14.9M | −$4.5M | −23.18% |
| Q3 2021 | 2021-09-30 | $11.6M | −$10.5M | −47.55% |
| Q2 2021 | 2021-06-30 | $19.2M | −$1.2M | −6.10% |
| Q1 2021 | 2021-03-31 | $13.5M | −$8.1M | −37.71% |
| Q4 2020 | 2020-12-31 | $19.4M | −$8.7M | −31.03% |
| Q3 2020 | 2020-09-30 | $22.2M | −$7.2M | −24.59% |
| Q2 2020 | 2020-06-30 | $20.4M | −$14.3M | −41.12% |
| Q1 2020 | 2020-03-31 | $21.6M | −$15.8M | −42.21% |
| Q4 2019 | 2019-12-31 | $28.1M | −$2.8M | −9.17% |
| Q3 2019 | 2019-09-30 | $29.4M | $128,000 | +0.44% |
| Q2 2019 | 2019-06-30 | $34.7M | $4.9M | +16.46% |
| Q1 2019 | 2019-03-31 | $37.4M | $12.1M | +47.85% |
| Q4 2018 | 2018-12-31 | $30.9M | — | — |
| Q3 2018 | 2018-09-30 | $29.3M | — | — |
| Q2 2018 | 2018-06-30 | $29.8M | — | — |
| Q1 2018 | 2018-03-31 | $25.3M | — | — |
Cyclerion Therapeutics operating expenses trends
Over the last five fiscal years, Cyclerion Therapeutics's operating expenses decreased from $83.6M to $7.0M, a change of −$76.5M. The latest reported quarter, Q2 2026, shows $1.8M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cyclerion Therapeutics source filings ↗